Edition:
United States

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

14.04USD
22 Sep 2017
Change (% chg)

$-0.39 (-2.70%)
Prev Close
$14.43
Open
$14.40
Day's High
$14.49
Day's Low
$13.89
Volume
40,108
Avg. Vol
45,903
52-wk High
$19.10
52-wk Low
$7.14

Latest Key Developments (Source: Significant Developments)

Concert Pharma pays total of $30.8 mln to Hercules Capital
Friday, 8 Sep 2017 07:38am EDT 

Sept 8 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharmaceuticals- ‍on Sept 7, paid total of $30.8 million to hercules capital outstanding under loan and security agreement with Hercules dated June 8.Concert Pharmaceuticals-upon payment of $30.8 million outstanding indebtedness, obligations of co owed to hercules were paid in full​.  Full Article

Concert Pharmaceuticals reports Q2 loss per share $0.58
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals reports second quarter 2017 financial results and provides company update.Q2 loss per share $0.58.Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.Concert Pharmaceuticals Inc - ‍company believes pro forma cash will be sufficient to fund company into 2021​.  Full Article

Concert Pharmaceuticals terminates Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement
Monday, 24 Jul 2017 07:00am EDT 

July 24 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals announces termination of the Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement with Vertex.Expiration of Hart-Scott-Rodino act waiting period represents final regulatory closing condition required to complete asset purchase.Termination for pending sale of CTP-656 and other assets related to treatment of cystic fibrosis by Concert to Vertex Pharmaceuticals.  Full Article

Concert Pharma says FDA lifts clinical hold on its clinical trial with CTP-543
Monday, 10 Jul 2017 07:30am EDT 

July 10 (Reuters) - Concert Pharmaceuticals Inc :Fda lifts clinical hold on concert pharmaceuticals clinical trial with ctp-543.Concert pharmaceuticals inc - ‍concert to resume enrollment in modified phase 2a trial for alopecia areata​.Concert pharmaceuticals inc - ‍company will amend protocol for phase 2a trial to evaluate two doses of ctp-543​.Concert pharmaceuticals inc - ‍expects to complete phase 2a trial second half of 2018​.  Full Article

Concert pharmaceuticals announces $30 million venture debt financing from hercules capital
Monday, 12 Jun 2017 07:00am EDT 

June 12 (Reuters) - Concert Pharmaceuticals Inc :Concert pharmaceuticals announces $30 million venture debt financing from Hercules Capital.Continue to expect to realize $160 million in connection with closing of CTP-656 asset purchase agreement with Vertex Pharmaceuticals.Debt is in form of a secured loan, secured by concert's assets, excluding intellectual property, and bearing interest of 8.55 pct.Loan will mature on June 1, 2021.  Full Article

Concert Pharmaceuticals announces departure of CFO, Ryan Daws
Tuesday, 30 May 2017 07:00am EDT 

May 30 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharmaceuticals announces departure of chief financial officer, Ryan Daws.Concert Pharmaceuticals Inc - concert has initiated a search to appoint a new CFO.Concert Pharmaceuticals - Daws will continue to consult with co, including through closing of pending asset purchase agreement with vertex pharmaceuticals, inc.  Full Article

Vertex Pharmaceuticals says FTC requested for additional information on pending acquisition from Concert Pharmaceuticals
Monday, 22 May 2017 08:07am EDT 

May 22 (Reuters) - Concert Pharmaceuticals Inc :Vertex Pharmaceuticals says on May 19, the U.S. FTC issued a request for additional information in connection co's pending acquisition of CTP-656 and other assets from Concert Pharmaceuticals.The second request was issued under notification requirements of the Hart-Scott-Rodino antitrust improvements act.Vertex Pharmaceuticals says it intends to work cooperatively with the FTC as it reviews the transaction.  Full Article

Concert Pharmaceuticals receives second request from FTC under Hart-Scott-Rodino Act
Monday, 22 May 2017 07:00am EDT 

May 22 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals receives second request from FTC under Hart-Scott-Rodino Act.Concert Pharmaceuticals Inc - Concert intends to work cooperatively with FTC as it reviews transaction.Says received a request for additional information from FTC in connection with pending acquisition of CTP-656.  Full Article

FDA puts clinical hold on Concert Pharma's hair loss drug
Wednesday, 17 May 2017 07:30am EDT 

May 17 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharmaceuticals announces clinical hold on ctp-543 phase 2A trial.Concert Pharmaceuticals says FDA requested review of recently completed non-clinical studies.Concert Pharmaceuticals - FDA requested review of recently completed non-clinical studies.Concert Pharmaceuticals - FDA did not cite a safety concern.Concert Pharmaceuticals - at request of FDA, company intends to submit requested non-clinical study reports promptly.Concert Pharmaceuticals - FDA intend to review additional non-clinical data as support for one-year dosing duration as planned in phase 2a trial.Concert Pharmaceuticals - received notice from U.S. FDA that its ctp-543 phase 2a clinical trial for alopecia areata has been placed on clinical hold.  Full Article

Concert Pharmaceuticals Q1 loss $0.60/shr
Tuesday, 2 May 2017 07:00am EDT 

May 2 (Reuters) - Concert Pharmaceuticals Inc :Concert pharmaceuticals reports first quarter 2017 financial results.Q1 loss per share $0.60.Q1 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Concert pharmaceuticals- cash, cash equivalents,investments as of march 31, 2017, totaled $83.9 million as compared to $96.2 million as of december 31, 2016.Concert pharmaceuticals - expects its cash, cash equivalents and investments as of march 31, 2017 to be sufficient to fund company through q2 of 2018.  Full Article

BRIEF-Concert Pharma pays total of $30.8 mln to Hercules Capital

* Concert Pharmaceuticals- ‍on Sept 7, paid total of $30.8 million to hercules capital outstanding under loan and security agreement with Hercules dated June 8